medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2016, Number 6

<< Back Next >>

Rev Invest Clin 2016; 68 (6)

The Neuroprotective Effect of Erythropoietin in Rat Hippocampus in an Endotoxic Shock Model

Ramírez-Jirano LJ, Zenteno-Savín T, Gaxiola-Robles R, Ramos-González EJ, Torres-Mendoza BM, Bitzer-Quintero OK

Language: Spanish
References: 31
Page: 292-298
PDF size: 247.93 Kb.


ABSTRACT

Background: Sepsis is characterized by an early systemic inflammation in response to infection. In the brain, inflammation is associated with expression of pro-inflammatory cytokines (e.g. tumor necrosis factor-α, interleukin-1β and interleukin-6, among others) that may induce an overproduction of reactive oxygen and nitrogen species. The constitutive expression of cytokines in the brain is low, but may be induced by various stimuli, including lipopolysaccharide, which causes neuronal damage. Erythropoietin, among other effects, acts as a multifunctional neurotrophic factor implicated in neurogenesis, angiogenesis, vascular permeability, and immune regulation in the central nervous system. In an experimental model of endotoxic shock, we studied the neuroprotective capacity of erythropoietin in the rat hippocampus and compared with melatonin, a neurohormone with an important antioxidant and immunomodulatory effect. Methods: In 21-day-old male Wistar rats divided into eight groups, we administered by intraperitoneal injection lipopolysaccharide, erythropoietin, melatonin, or combinations thereof. The hippocampus was dissected and morphological (histological analysis) and biochemical (cytokine levels) studies were conducted. Results: The number of dead neuronal cells in histological sections in groups treated with lipopolysaccharide was higher compared to the erythropoietin group. There was a greater decrease (70%) in interleukin-1β concentrations in rats with endotoxic shock that received erythropoietin compared to the lipopolysaccharide group. Conclusions: The neuronal cell loss caused by endotoxic shock and interleukin-1β levels were reduced by the administration of the hematopoietic cytokine erythropoietin in this experimental model.


REFERENCES

  1. Tschoeke SK, Oberholzer A, Moldawer LL, Interleukin-18: A novel prognostic cytokine in bacteria-induced sepsis. Crit Care Med. 2006;34:1225-33.

  2. Steinman L. Elaborate interactions between the immune system and nervous system. Nat Immunol. 2004;5:575-81.

  3. Wrona D. Neural-immune interactions. An integrative view of the directional relationships between the brain and immune system. J Neuroimmunol. 2006;172:38-58.

  4. Haddad JJ, Saade NE, Safich-Garabedian B. Cytokines and neuro- immune-endocrine interactions: a role for the hypothalamicpituitary- adrenal revolving axis. J Neuroimmunol. 2002;133:1-19.

  5. Schultzberg M, Lindberg C, Aronsson AF. Inflammation in the nervous system- physiological and pathophysiological aspects. Behavior. 2007;92:121-8.

  6. Immune Surveillance of the Human Central Nervous System (CNS): Different Migration Pathways of Immune Cells through the Blood-Brain Barrier and Blood-Cerebrospinal Fluid Barrier in Healthy Persons. Cytometry Part. 2006;69:147-51.

  7. Czapski GA, Gajkowska B, Strosznajder JB. Systemic administration of lipopolysaccharide induces molecular and morphological alterations in the hippocampus. Brain Res. 2010;1356:85-94.

  8. Semmler A, Hermann S, Mormann F, et al. Sepsis causes neuroinflammation and concomitant decrease of cerebral metabolism. J Neuroinflammation. 2008;5:38.

  9. Sharshar T, Hopkinson NS, Orlikowski D, Annane D. Science review: The brain in sepsis--culprit and victim. Crit Care. 2005;9: 37-44.

  10. Taupin P. The hippocampus: neurotransmission and plasticity in the nervous system. 2007, New York: Nova Biomedical Books. p 144.

  11. Cavaglia M, Dombrowski SM, Drazba J, Vasanji A, Bokesch PM, Janigro D. Regional variation in brain capillary density and vascular response to ischemia. Brain Res. 2001;910:81-93.

  12. Ouyang YB, Voloboueva LA, Xu LJ, Giffard RG. Selective dysfunction of hippocampal CA1 astrocytes contributes to delayed neuronal damage after transient forebrain ischemia. J Neurosci. 2007;27:4253-60.

  13. Buemi M, Caccamo C, Nostro L, Cavallaro E, Floccari F, Grasso G. Brain and cancer: the protective role of erythropoietin. Med Res Rev. 2005;25:245-59.

  14. Buemi M, Cavallaro E, Floccari F, et al. Erythropoietin and the brain: from neurodevelopment to neuroprotection. Clin Sci (Lond). 2002;103:275-82.

  15. Hojman P, Taudorf S, Lundby C, Pedersen BK. Erythropoietin augments the cytokine response to acute endotoxin-induced inflammation in humans. Cytokine. 2009;45:154-7.

  16. Joyeux-Faure M. Cellular protection by erythropoietin: new therapeutic implications. J Pharmacol Exp Ther. 2007;323:759-62.

  17. Wilms H, Schwabedissen B, Sievers J, Lucius R. Erythropoietin does not attenuate cytokine production and inflammation in microglia-implications for the neuroprotective effect of erythropoietin in neurological diseases. J Neuroimmunol. 2009;212: 106-11.

  18. Bitzer-Quintero OK, Dávalos-Marín AJ, Ortiz GG, et al. Antioxidant activity of tryptophan in rats under experimental endotoxic shock. Biomed Pharmacother. 2010;64:77-81.

  19. Srinivasan V, Pandi-Perumal SR, Spence DW, Kato H, Cardinali DP. Melatonin in septic shock: some recent concepts. J Crit Care. 2010;25:656.e1-6.

  20. Srinivasan V, Mohamed M, Kato H. Melatonin in bacterial and viral infections with focus on sepsis: a review. Recent Pat Endocr Metab Immune Drug Discov. 2012;6:30-9.

  21. Tao W, Wen F, Zhang H, Liu G. The signal transduction mediated by erythropoietin and proinflammatory cytokines in the JAK/STAT pathway in the children with cerebral palsy. Brain Dev. 2009;31:200-7.

  22. Tonges L, Schlachetzki JC, Weishaupt JH, Bhar M. Hematopoietic cytokines-on the verge of conquering neurology. Curr Mol Med. 2007;7:157-70.

  23. Feria-Velasco A, Karnovsky MJ. Optimal central nervous system preservation with glutaraldehyde perfusion for ultrastructural study. Arch Invest Med (Mex). 1970;1:201-20.

  24. Abramoff MD, Magelhaes PJ, Ram SJ. Image Processing with ImageJ. Biophotonics Int. 2004;11:36-42.

  25. Towfighi J, Mauger D. Temporal evolution of neuronal changes in cerebral hypoxia-ischemia in developing rats: a quantitative light microscopic study. Brain Res Dev Brain Res. 1998;109:169-77.

  26. Maiese K, Chong ZZ, Shang YCh, Wang S. Erythropoietin: New directions for the nervous system. Int J Mol Sci. 2012;13: 11102-29.

  27. Hatshell S, RowlandsT, Hiremath M, Cowin P. Beta-catenin and Tcfs in mammary development and cancer. J Mammary Gland Biol Neoplasia. 2003;8:145-58.

  28. Byts N, Sirén A-L. Erythropoietin: a multimodal neuroprotective agent. Exp Transl Stroke Med. 2009;1:4.

  29. Hellewell SC, Yan EB, Alwis DS, Bye N, Morganti-Kossmann MC. Erythropoietin improves motor and cognitive deficit, axonal pathology, and neuroinflammation in a combined model of diffuse traumatic brain injury and hypoxia, in association with upregulation of the erythropoietin receptor. J Neuroinflammation. 2013; 10:156.

  30. Ponce LL, Navarro JC, Ahmed O, Robertson CS. Erythropoietin neuroprotection with traumatic brain injury. Pathophysiol. 2013; 20:31-8.

  31. Sun Y, Calvert JW, Zhang JH. Neonatal hypoxia/ischemia is associated with decreased inflammatory mediators, after erythropoietin administration. Stroke. 2005;36:1672-8.




2020     |     www.medigraphic.com